Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Insulet Reports Full Year 2019 Revenue of $738.2 Million, an Increase of 31%, and Fourth Quarter 2019 Revenue of $209.4 Million, an Increase of 27% Year-Over-Year
ACTON, Mass. --(BUSINESS WIRE)--Feb. 25, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced financial results for the three months and full year
View HTML
Toggle Summary Insulet to Present at Upcoming Investor Conferences
ACTON, Mass. --(BUSINESS WIRE)--Feb. 24, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at four upcoming investor conferences (all times below are
View HTML
Toggle Summary Dexcom and Insulet Announce Commercial Agreement to Integrate the Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System
First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control Initially compatible with Dexcom G6 CGM, with no fingersticks* required Integration with the next generation Dexcom G7 CGM system, once available SAN DIEGO & ACTON, Mass.
View HTML
Toggle Summary Abbott and Insulet Partner to Integrate Next-Generation Glucose Sensing and Automated Insulin Delivery Technologies for Seamless Diabetes Care
- Collaboration will combine Abbott's leading continuous glucose monitoring (CGM) technology with Insulet's Omnipod Horizon™ Automated Insulin Delivery System to offer an accurate, easy-to-use, integrated digital health platform - Integrated technology will provide people living with diabetes
View HTML
Toggle Summary Insulet Issues Medical Device Correction Regarding its Omnipod DASH™ Insulin Management System
ACTON, Mass. --(BUSINESS WIRE)--Feb. 13, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced a voluntary Medical Device Correction for all Omnipod DASH™ Personal
View HTML
Toggle Summary Medical Device Correction Investor FAQs
Does this mean you will replace all the current Omnipod DASH™ PDMs in the field? A software update is being developed to provide a solution for this issue and is expected to be available starting March 2020. We will provide new PDMs containing the software update to all Omnipod DASH™ users and we
View HTML
Toggle Summary Insulet to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
ACTON, Mass. --(BUSINESS WIRE)--Jan. 6, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced plans to release its financial results for the fourth quarter and full
View HTML
Toggle Summary Insulet to Present at 38th Annual J.P. Morgan Healthcare Conference
ACTON, Mass. --(BUSINESS WIRE)--Dec. 20, 2019-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at the 38 th Annual J.P.
View HTML
Toggle Summary First Patients in Europe Start Using Insulet’s New Omnipod DASH™ Insulin Management System in the UK and the Netherlands
LONDON --(BUSINESS WIRE)--Dec. 18, 2019-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced the launch of the new Omnipod DASH™ Insulin Management System
View HTML
Toggle Summary Insulet to Present at Upcoming Investor Conferences
ACTON, Mass. --(BUSINESS WIRE)--Nov. 7, 2019-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at two upcoming investor conferences: The 2019 Stephens
View HTML
Toggle Summary Insulet Reports Third Quarter 2019 Revenue of $192 Million, an Increase of 27% Year-Over-Year
ACTON, Mass. --(BUSINESS WIRE)--Nov. 5, 2019-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced financial results for the three months ended September
View HTML
Toggle Summary Fiasp® Rapid Acting Insulin for Adults Now Approved for Use With the Omnipod Insulin Management System Platform in the United States
Insulet Further Demonstrating Commitment to Innovation and Patient Choice ACTON, Mass. --(BUSINESS WIRE)--Oct. 25, 2019-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today
View HTML
Toggle Summary Insulet to Announce Third Quarter 2019 Financial Results on November 5, 2019
  ACTON, Mass. --(BUSINESS WIRE)--Sep. 30, 2019-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced plans to release its financial results for the third quarter of 2019 on
View HTML
Toggle Summary Insulet’s Omnipod DASH™ System Now FDA Cleared as an Alternate Controller Enabled (ACE) Infusion Pump
  ACTON, Mass. --(BUSINESS WIRE)--Sep. 23, 2019-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced it has received clearance from the U.S.
View HTML
Toggle Summary Insulet Announces Pricing of Convertible Senior Notes Due 2026
ACTON, Mass. --(BUSINESS WIRE)--Sep. 4, 2019-- Insulet Corporation (NASDAQ:PODD) ( Insulet or the Company), a leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), has priced a private placement of $700 million aggregate principal amount of
View HTML